AZD8055: Practical Guidance for Preclinical mTOR Inhibition

What This Product Solves

AZD8055 (CAS 1009298-09-2, AZD8055) is a potent and highly selective ATP-competitive mTOR inhibitor. It is engineered for rigorous dissection of the mTORC1 and mTORC2 signaling pathways in cellular and animal models. Given its exceptional selectivity (IC50 0.8 nM for mTOR; ~1000-fold over PI3K isoforms and ATM/DNA-PK) and lack of activity on a broad kinase panel at 10 μM, AZD8055 enables researchers to study downstream effects of mTOR inhibition with minimal confounding kinase off-target effects. This compound is particularly suitable for workflows examining cancer cell proliferation, metabolic modulation, and pathway cross-talk, where precise inhibition of mTOR complexes is critical. However, it is not recommended for translational or clinical efficacy studies, as preclinical promise did not translate into meaningful benefit in phase I trials.

For broader technical context and troubleshooting advice, see "AZD8055: Practical Use of a Selective mTOR Inhibitor in Research", which details best practices for pathway interrogation, and "AZD8055: Technical Guidance for mTOR Signaling Pathway Inhibition", which summarizes workflow discipline for reproducibility.

Protocol Parameters

• Assay: In vitro cell proliferation inhibition | Value: Nanomolar concentrations (as low as 0.8 nM for mTOR IC50) | Applicability: Cancer cell lines including breast, lung, and leukemia | Rationale: Enables suppression of proliferation markers (e.g., Ki67) at low concentrations | Source type: Product dossier
• Assay: In vivo administration (mouse xenograft models) | Value: Intraperitoneal injection; dose and schedule per local IACUC and pilot titration | Applicability: Tumor growth inhibition and metabolic readouts in preclinical cancer models | Rationale: Demonstrated modulation of tumor burden and glucose/insulin parameters | Source type: Product dossier + workflow recommendation
• Assay: Compound solubilization for stock solution | Value: ≥23.3 mg/mL in DMSO; insoluble in water/ethanol | Applicability: Preparation of concentrated stocks for in vitro and in vivo use | Rationale: Ensures complete dissolution and reproducible dosing | Source type: Product dossier
• Assay: Storage conditions | Value: Store solid at -20°C; avoid long-term storage of solutions | Applicability: Stock material and working solutions | Rationale: Maintains chemical integrity; minimizes degradation | Source type: Product dossier

Workflow Setup and QC Checklist

• Stock Preparation: Dissolve AZD8055 in 100% DMSO to make concentrated stock (e.g., 10–20 mM); vortex and sonicate if needed. Avoid aqueous or ethanol solutions due to insolubility.
• Aliquoting and Storage: Aliquot stocks to minimize freeze-thaw cycles. Store sealed, desiccated, and protected from light at -20°C. Discard any solution stored long-term or showing precipitation.
• Working Solution Preparation: Dilute stock into pre-warmed cell culture medium or injection buffer immediately prior to use, maintaining final DMSO concentration ≤0.1% (v/v) in cell-based assays to reduce solvent effects.
• Negative and Vehicle Controls: Always include DMSO-only vehicle controls at equivalent concentrations to the highest used in treatment groups.
• QC Verification: Confirm AZD8055 identity by lot and molecular weight (465.54 Da) before experimental use. Visually inspect for precipitation or color change in solutions.
• Experimental Replicates: For reliable signal detection, run biological triplicates and technical duplicates at minimum. Include positive controls if possible (e.g., alternative mTOR inhibitors for benchmarking).

Common Failure Modes and Fixes

• Incomplete Solubilization: If AZD8055 does not dissolve fully in DMSO, warm gently and vortex. Avoid water or ethanol. If undissolved particles remain, filter using a 0.2 μm PTFE filter before aliquoting.
• Loss of Activity: Do not store working solutions; prepare fresh dilutions each session. Activity loss may occur due to repeated freeze-thaw cycles or prolonged exposure to light. Use amber vials if light sensitivity is suspected.
• Cellular Toxicity Unrelated to mTOR Inhibition: Excessive DMSO (>0.1% v/v) or compound precipitation can cause non-specific toxicity. Confirm solubility at all working concentrations and match vehicle concentrations in all controls.
• Variable In Vivo Response: Optimize dosing and schedule based on pilot studies and current literature for the specific animal model, as pharmacokinetics may vary with formulation and route.
• Interference in Readouts: AZD8055 may alter metabolic endpoints (e.g., glucose/insulin), which could confound interpretation in metabolic studies. Include appropriate baseline and longitudinal controls.

Scope and Limitations

AZD8055 is designed for preclinical research focused on mechanistic interrogation of the mTOR signaling pathway, specifically in cancer cell lines and animal models. Its selectivity profile makes it ideal for studies dissecting both mTORC1 and mTORC2 function, as well as downstream effects on cell proliferation and metabolism. However, it is not appropriate for translational or clinical efficacy studies due to minimal benefit observed in phase I trials. The compound should not be used in workflows that require water- or ethanol-based solubilization, nor should it be stored in solution for extended periods. Researchers must also consider that systemic metabolic effects may complicate interpretation in multi-parametric studies.

APExBIO provides AZD8055 as a research-use-only reagent; it is not for human or veterinary use. For further technical guidance, refer to the product information page.

Conclusion

AZD8055 enables rigorous, selective inhibition of both mTORC1 and mTORC2, supporting detailed mechanistic studies in cancer and metabolic research. Its high selectivity and potency reduce off-target effects, making it a reliable tool for dissecting the PI3K/Akt/mTOR axis. Proper solubilization, storage, and quality control are essential to ensure reproducibility and data validity. Researchers should restrict use to preclinical and mechanistic settings, and avoid employing AZD8055 for clinical endpoint studies. For a complete product dossier and ordering information, consult APExBIO.